marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-08-2024
Oncternal Therapeutics Balance Sheet 2011-2024 | ONCT
Annual Balance Sheet Oncternal Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6.38 M | - | - | -117 M | -19.9 M | -28.3 M | -15.8 M | -8.91 M | -14.1 M | -17.9 M | -14.5 M | -48 M | -63.7 M |
Long Term Debt |
145 K | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
173 K | 87 K | 75 K | 40 K | 99 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 91 K | - | - | - | - | 30 K | 354 K | 578 K | 234 K |
Total Current Liabilities |
5.2 M | 7.68 M | 5.46 M | 5.86 M | 7.34 M | 5.21 M | 7.98 M | 4.61 M | 30.2 M | 32.8 M | 4.57 M | 9.5 M | 6.08 M |
Total Liabilities |
6.68 M | 7.68 M | - | 5.86 M | 7.43 M | 5.21 M | 7.98 M | 4.61 M | 30.2 M | 32.8 M | 4.92 M | 10.1 M | 6.31 M |
Deferred Revenue |
- | - | - | 1.63 M | 3.64 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-198 M | -158 M | -114 M | -82.8 M | -65.6 M | -600 M | -562 M | -531 M | -513 M | -495 M | -455 M | -413 M | -386 M |
Total Assets |
36.7 M | 68.7 M | 93.6 M | 119 M | 21.7 M | 31.3 M | 46.2 M | 24.5 M | 32 M | 50.7 M | 15.6 M | 57.8 M | 78.2 M |
Cash and Cash Equivalents |
6.7 M | 37.1 M | 90.8 M | 117 M | 20.1 M | 28.3 M | 15.8 M | 8.91 M | 14.1 M | 17.9 M | 14.5 M | 48 M | 63.7 M |
Book Value |
30.1 M | 61 M | 93.6 M | 113 M | 14.3 M | 26.1 M | 38.3 M | 19.9 M | 1.86 M | 17.8 M | 10.7 M | 47.7 M | 71.9 M |
Total Shareholders Equity |
30.1 M | 61 M | 88.1 M | 113 M | 14.3 M | -29.6 M | 38.3 M | 19.9 M | 1.86 M | 17.8 M | 10.7 M | 47.7 M | 71.9 M |
All numbers in USD currency
Quarterly Balance Sheet Oncternal Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
50 K | 99 K | 145 K | 191 K | 221 K | - | - | - | 13 K | - | - | - | - | 31 K | - | 79 K | 117 K | 53 K | 91 K | 91 K | 91 K | 91 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.1 M | 6.22 M | 6.68 M | 6.2 M | 5.59 M | - | 7.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-215 M | -206 M | -198 M | -189 M | -179 M | -170 M | -158 M | -147 M | -136 M | -124 M | -114 M | -106 M | -96.4 M | -88.7 M | -82.8 M | -82.8 M | -82.8 M | -82.8 M | -65.6 M | -65.6 M | -65.6 M | -65.6 M | -31.4 M | -31.4 M | -31.4 M | -600 M | -562 M | -562 M | -562 M | -562 M | -531 M | -531 M | -531 M | -531 M | -513 M | -513 M | -513 M | -513 M | -495 M | -495 M | -495 M | -495 M | -455 M | -455 M | -455 M | -455 M | -413 M | -413 M | -413 M | -413 M | -386 M | -386 M | -386 M | -386 M |
Total Assets |
23.9 M | 29.1 M | 36.7 M | 43.2 M | 50.8 M | 58.3 M | 68.7 M | 76.2 M | 81.5 M | 85.5 M | 93.6 M | 100 M | 108 M | 114 M | 119 M | 119 M | 119 M | 119 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 22 M | 22 M | 22 M | 31.3 M | 46.2 M | 46.2 M | 46.2 M | 46.2 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | 32 M | 32 M | 32 M | 32 M | 50.7 M | 50.7 M | 50.7 M | 50.7 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 78.7 M | 78.2 M | 78.2 M | 78.2 M |
Cash and Cash Equivalents |
6.38 M | 6.4 M | 6.7 M | 14.9 M | 15.8 M | 11.2 M | 37.1 M | 70.6 M | 78.9 M | 82.2 M | 90.8 M | 97.4 M | 104 M | 111 M | 117 M | 117 M | 117 M | 117 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 20.6 M | 20.6 M | 20.6 M | 28.3 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | 8.91 M | 8.91 M | 8.91 M | 8.91 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 48 M | 48 M | 48 M | 48 M | 63.7 M | 63.7 M | 63.7 M | 63.7 M |
Book Value |
15.8 M | 22.9 M | 30.1 M | 37 M | 45.2 M | 58.3 M | 61 M | 76.2 M | 81.5 M | 85.5 M | 93.6 M | 100 M | 108 M | 114 M | 119 M | 119 M | 119 M | 119 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 22 M | 22 M | 22 M | 31.3 M | 46.2 M | 46.2 M | 46.2 M | 46.2 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | 32 M | 32 M | 32 M | 32 M | 50.7 M | 50.7 M | 50.7 M | 50.7 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 78.7 M | 78.2 M | 78.2 M | 78.2 M |
Total Shareholders Equity |
15.8 M | 22.9 M | 30.1 M | 37 M | 45.2 M | 52.5 M | 61 M | 68.5 M | 74 M | 80.2 M | 88.1 M | 94.5 M | 103 M | 108 M | 113 M | 113 M | 113 M | 113 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | -29.6 M | -29.6 M | -29.6 M | 26.1 M | -23.3 M | 38.3 M | 38.3 M | 38.3 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 1.86 M | 1.86 M | 1.86 M | 1.86 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 71.9 M | 71.9 M | 71.9 M | 71.9 M |
All numbers in USD currency